NDS and NSS for Screening Diabetic Neuropathy
Key facts
- Who runs it
- Chulalongkorn University
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 228 people enrolled
- Started
- 14 Mar 2024
- Ended
- 13 Mar 2026
- Type of study
- Observational
- Record updated
- 29 April 2026
Who can take part
- Age
- 30 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 30 to 65 years
- Diagnosed with diabetes mellitus (type 1 or type 2) by a physician
- Able and willing to provide informed consent
- Willing to undergo clinical evaluation and neurophysiological testing, including nerve conduction studies
Who cannot take part
- Exposure to neurotoxic agents (e.g., drugs, heavy metals)
- History of other causes of peripheral neuropathy (e.g., nutritional deficiency, alcohol-related neuropathy, chronic kidney disease)
- Known neuromuscular or neurological disorders (e.g., myopathy, hereditary neuropathy, Guillain-Barré syndrome, chronic inflammatory neuropathy)
- Presence of lower limb conditions interfering with assessment (e.g., amputation, chronic wounds, significant edema)
- Inability to communicate or complete study procedures
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Diabetic sensorimotor polyneuropathy is a common complication of diabetes mellitus that can lead to pain, sensory loss, foot ulcers, and disability. Early detection is important, but standard diagnostic tests such as nerve conduction studies are not always easily accessible in routine clinical practice.
Read full original descriptionShow less
This study aims to evaluate the accuracy and reliability of two simple clinical tools, the Neuropathy Disability Score (NDS) and the Neuropathy Symptom Score (NSS), for screening diabetic peripheral neuropathy. These tools are based on patient-reported symptoms and bedside neurological examination and may provide a practical alternative for early detection.
In this cross-sectional diagnostic accuracy study, adult patients with diabetes will be recruited from King Chulalongkorn Memorial Hospital. Participants will undergo clinical assessments, questionnaires, laboratory investigations, and neurophysiological testing, including nerve conduction studies, which will serve as the reference standard. The performance of NDS and NSS will be analyzed to determine their sensitivity, specificity, and overall diagnostic value.
The results of this study may support the use of simple, accessible screening tools for early identification of diabetic neuropathy, potentially improving patient care and reducing complications.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Utilizing the Neuropathy Disability Score and Neuropathy Symptom Score for Screening Diabetic Sensorimotor Polyneuropathy
- Record updated
- 29 April 2026